Oncology

Data from a phase 1a/1b trial support additional research on dual TIGIT/PD-L1 inhibition in patients with advanced solid tumors.

Rates of treatment discontinuation appear to be higher in patients receiving nivolumab plus ipilimumab for cancer than those receiving nivolumab monotherapy.

The FDA companion diagnostic designation for FoundationOne CDx may improve access to treatment with selpercatinib in select patients with solid tumors harboring a RET gene fusion.

Julie M. Vose, MD, MBA, discussed why the need for multidisciplinary care is so pertinent, and how it must continue even after treatment ends.

A biologic license application supplement resubmission for the pegfilgrastim-cbqv on-body injector follows the resolution of inspection findings highlighted in a complete response letter from the FDA.

In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.

Lucio N. Gordan, MD, reviews how the chemotherapy drug shortages have led to price gouging, potentially making treatment unavailable to patients.

The FDA has not requested any additional data or clinical trials supporting the supplemental biologics license application for an on-body injector presentation of pegfilgrastim-cbqv.

Community health worker–led intervention may yield improvements in patient activation, hospice use, and total health care costs compared with usual care in those with newly diagnosed cancer.

Findings from the PRO-TECT trial suggest that patients and nurses are generally in favor of implementing financial toxicity screening into routine care for cancer.

Findings from a meta-analysis indicate that interventions for caregivers of patients with advanced cancer may improve self-efficacy and grief.

Pharmaceutical, gynecologic oncology, and physician perspectives shed light on potentially mitigating the ongoing carboplatin and cisplatin shortages’ effects on cancer care in the United States.

Co-editor-in-chief, Howard S. Hochster, MD, reviews the ongoing drug price negotiations and the effect it will have in the health care space.

The FDA okayed 2 breakthrough therapy designations for fam-trastuzumab deruxtecan-nxki in HER2-positive solid tumors and colorectal cancer, which are based on data from the phase 2 DESTINY-PanTumor02 and DESTINY-CRC02 trials.

Implementing tax benefits for manufacturers who produce chemotherapy drugs may be one solution to increase drug production in the United States, according to Lucio N. Gordan, MD.

Lucio N. Gordan, MD, describes how his practice deals with increasing costs of limited chemotherapy agents to ensure that patients with cancer continue to receive treatment.

Lucio N. Gordan, MD, also discusses how increasing domestic manufacturing of chemotherapy may help in alleviating the ongoing shortages of carboplatin and cisplatin in the United States.

Treatment with divarasib appears to produce a manageable safety profile of low-grade toxicities in patients with advanced or metastatic KRAS G12C–mutated solid tumors.

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, believes that national legislation can help to resolve the United States’ current dearth of cisplatin, as well as prevent future problems.

Using an AUC of 5 instead of an AUC of 6 can help to conserve cisplatin among patients with cancer, Kirollos Hanna, PharmD, BCPS, BCOP, FACCC says.

Investigators of a cohort study report that the withdrawal rate from clinical trials in oncology appear to be higher among Hispanic patients and across placebo-controlled trials, but lower in trials with radiation use as part of therapy.

The HLA-LOH test makes use of data produced with the xT CDx assay to identify patients with tumors experiencing allele-specific loss of heterozygosity who may benefit from specific targeted treatments.

In the August Letter to Readers, Julie M. Vose, MD, MBA, discusses the recent cisplatin shortages and how this can be mitigated in the future.

Physician burnout is not just a phase, but rather a mental health issue that has made itself well-known in the medical community, with many clinicians trying to find strategies to cope with it.

Data from a phase 2 trial support a supplemental new drug application for isavuconazonium sulfate as a treatment for pediatric patients with invasive aspergillosis or invasive mucormycosis.